Key result
Simplified stellate ganglion-sparing left cardiac sympathetic denervation is linked to ~86% fewer ICD-treated VA episodes.
Why the study?
A simplified cardiac sympathetic denervation approach sparing the stellate ganglion and targeting left T2-T4 ganglia needed evaluation as a less invasive bailout procedure for refractory recurrent ventricular arrhythmias in multimorbid patients with structural heart disease.
Does simplified SG-sparing left cardiac sympathetic denervation reduce recurrent ventricular arrhythmias in multimorbid patients with structural heart disease?
Observational (n=7)
No
Does simplified SG-sparing left cardiac sympathetic denervation reduce recurrent ventricular arrhythmias in multimorbid patients with structural heart disease?
Answers are grounded in this paper and cite their sources.
Simplified SG-sparing left cardiac sympathetic denervation appears safe and significantly reduces ventricular arrhythmia episodes and ICD shocks in multimorbid patients with structural heart disease.
Background Cardiac sympathetic denervation as a treatment for drug-refractory ventricular arrhythmias (VAs) involves video-assisted thoracoscopic removal of the stellate ganglion (SG) and thoracic ganglia. A simplified approach sparing the SG and targeting left T2–T4 ganglia (left cardiac sympathetic denervation [LCSD]) may offer a less invasive alternative. Objective This study aimed to evaluate the efficacy and safety of simplified SG-sparing LCSD as a bailout procedure for multimorbid patients with structural heart disease and recurrent VAs refractory to antiarrhythmic drugs and/or catheter ablation. Methods All patients undergoing SG-sparing LCSD at our institution between June 2023 and June 2024 were included in this single-center retrospective study. Baseline demographics, procedural complications, and arrhythmia outcomes were analyzed. Results LCSD was performed in 7 patients (mean age 75.9 ± 6.7 years, mean LVEF 30.7 ± 10.9%) with structural heart disease (nonischemic cardiomyopathy, n=3; ischemic cardiomyopathy, n=4) mostly 1 day (interquartile range 1–21) after admission with a procedure duration of 20.7 ± 5.3 minutes. Initially, 4 patients (57.1%) had electrical storm. Apart from 1 pleural effusion requiring drainage, no major complications or Horner's syndrome occurred. During a follow-up of 7 ± 2.6 months, median VA episodes requiring implantable cardioverter-defibrillator therapy decreased from 14 to 2 (P = .021) and median implantable cardioverter-defibrillator shocks from 1.5 to 0 (P = .034). Three patients remained free of sustained VAs; 1 patient died of coronavirus disease 2019. Conclusion In this case series of 7 patients, SG-sparing LCSD demonstrated promising results in terms of safety and efficacy for reducing VAs. Further studies are warranted to confirm long-term outcomes with this approach.
No takes yet. Share an insight, caveat, or question.
Krieger et al. (2025) conducted an observational in Recurrent ventricular tachycardia in multimorbid patients with structural heart disease (n=7). Simplified stellate ganglion-sparing left cardiac sympathetic denervation (LCSD) vs. Baseline was evaluated on Median ventricular arrhythmia episodes requiring implantable cardioverter-defibrillator therapy (p=.021). Simplified stellate ganglion-sparing left cardiac sympathetic denervation reduced median VA episodes requiring ICD therapy from 14 to 2 over 7 months in multimorbid patients.
Synapse has enriched 10 related papers. Consider them for comparative context: